Neuronetics, Inc.

For the period ended Dec 31, 2024. Filed Mar 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 27, 2025

STIM$2.18+1.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except per share data)


· · December 31,
· · 2024 · 2023
Assets · · ·
Current assets: · · ·
Cash and cash equivalents	$18,459	$59,677
Restricted cash	1,000	—
Accounts receivable, net of allowance of credit losses of $1,930 and $795 as of December 31, 2024 and 2023, respectively	23,355	15,782
Inventory	4,248	8,093
Current portion of net investments in sales-type leases	206	905
Current portion of prepaid commission expense	3,078	2,514
Current portion of notes receivable	930	2,056
Prepaid expenses and other current assets	6,846	4,766
Total current assets	58,122	93,793
Property and equipment, net	6,242	2,009
Goodwill	18,634	—
Intangible assets, net	19,606	—
Operating lease right-of-use assets	27,093	2,773
Net investments in sales-type leases	86	661
Prepaid commission expense	8,902	8,370
Long-term notes receivable	295	3,795
Other assets	1,923	4,430
Total assets	$140,903	$115,831
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$11,077	$4,752
Accrued expenses	12,818	12,595
Deferred revenue	974	1,620
Deferred and contingent consideration	1,000	—
Other payables	605	—
Current portion of operating lease liabilities	4,791	845
Total current liabilities	31,265	19,812
Long-term debt, net	55,151	59,283
Deferred revenue	2	200
Operating lease liabilities	22,686	2,346
Total liabilities	109,104	81,641
Commitments and contingencies (Note 20)
Stockholders’ equity:
Preferred stock, $0.01 par value: 10,000 shares authorized; no shares issued or outstanding on December 31, 2024 and December 31, 2023	—	—
Common stock, $0.01 par value: 250,000 shares authorized; 55,679 and 29,092 shares issued and outstanding on December 31, 2024 and December 31, 2023, respectively	557	291
Additional paid-in capital	446,938	409,980
Accumulated deficit	(419,789)	(376,081)
Total Stockholders' equity	27,706	34,190
Non-controlling interest	4,093	—
Total equity	31,799	34,190
Total liabilities and Stockholders’ equity	$140,903	$115,831

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.